| Pharmaceutical Information |
| Drug Name |
Prazosin |
| Drug ID |
BADD_D01827 |
| Description |
Prazosin, also known as _Minipress_, is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988 [L5828]. It belongs to the class of drugs known as alpha-1 antagonists [FDA label], [A176630].
Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares [A176618, A176621, A176624]. |
| Indications and Usage |
For treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
C02CA01 |
| DrugBank ID |
DB00457
|
| KEGG ID |
D08411
|
| MeSH ID |
D011224
|
| PubChem ID |
4893
|
| TTD Drug ID |
D0WV3U
|
| NDC Product Code |
Not Available |
| Synonyms |
Prazosin | Furazosin | Prazosin Hydrochloride | Hydrochloride, Prazosin | Prazosin HCL | HCL, Prazosin | Minipress | Pratsiol |
|
| Chemical Information |
| Molecular Formula |
C19H21N5O4 |
| CAS Registry Number |
19216-56-9 |
| SMILES |
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
